Novo Nordisk is investing further in obesity and metabolic disease, signing a deal to use Ascendis Pharma’s delivery ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a price target of $167.00. The company’s shares closed last ...

Novo Nordisk acquires exclusive worldwide license to Ascendis Pharma’s TransCon technology for developing metabolic and ...

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...